Plasmodium falciparum malaria
diseaseOn this page
Also known as falciparum malariafalciparum malaria [malignant tertian]malignant tertian fever (finding)Plasmodium falciparum malaria, unspecified
Summary
Plasmodium falciparum malaria (MONDO:0005920) is a disease and 112 clinical trials. Top therapeutic interventions include artesunate, primaquine, and amodiaquine. A subtype of malaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 112
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Plasmodium falciparum malaria |
| Mondo ID | MONDO:0005920 |
| EFO | EFO:0007444 |
| MeSH | D016778 |
| DOID | DOID:14067 |
| ICD-10-CM | B50 |
| NCIT | C34798 |
| SNOMED CT | 62676009 |
| UMLS | C0024535 |
| MedGen | 6185 |
| GARD | 0024254 |
| Is cancer (heuristic) | no |
Also known as: falciparum malaria · falciparum malaria [malignant tertian] · malignant tertian fever (finding) · Plasmodium falciparum malaria, unspecified
Disease family
This is a subtype of malaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › malaria › Plasmodium falciparum malaria
Related subtypes (6): Plasmodium ovale malaria, Plasmodium malariae malaria, mixed malaria, cerebral malaria, blackwater fever, Plasmodium vivax malaria
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 22 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Acetaminophen | Phase 3 (in late-stage trials) |
| Amodiaquine | Phase 3 (in late-stage trials) |
| Amoxicillin | Phase 3 (in late-stage trials) |
| Artemether | Phase 3 (in late-stage trials) |
| Artenimol | Phase 3 (in late-stage trials) |
| Artesunate | Phase 3 (in late-stage trials) |
| Atovaquone | Phase 3 (in late-stage trials) |
| Azithromycin | Phase 3 (in late-stage trials) |
| Chloroquine | Phase 3 (in late-stage trials) |
| Chlorproguanil | Phase 3 (in late-stage trials) |
| Dapsone | Phase 3 (in late-stage trials) |
| Lumefantrine | Phase 3 (in late-stage trials) |
| Lumefantrine Co-Artemether | Phase 3 (in late-stage trials) |
| Mefloquine | Phase 3 (in late-stage trials) |
| OZ277 | Phase 3 (in late-stage trials) |
| Piperaquine | Phase 3 (in late-stage trials) |
| Primaquine | Phase 3 (in late-stage trials) |
| Proguanil | Phase 3 (in late-stage trials) |
| Pyrimethamine | Phase 3 (in late-stage trials) |
| Pyronaridine | Phase 3 (in late-stage trials) |
| Quinine | Phase 3 (in late-stage trials) |
| Sulfadoxine | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Arginine Hydrochloride, Fosmidomycin, Imatinib, MATRIX-M1 ADJUVANT, Pentoxifylline, Rabies Vaccine, Sodium Chloride, Tafenoquine.
Clinical trials & evidence
Clinical trials
Clinical trials: 112.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 35 |
| PHASE1 | 26 |
| PHASE4 | 13 |
| PHASE2 | 12 |
| PHASE1/PHASE2 | 11 |
| PHASE3 | 10 |
| PHASE2/PHASE3 | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06068530 | PHASE4 | RECRUITING | Mass Vaccine and Drug Administration, Bangladesh |
| NCT07194668 | PHASE4 | NOT_YET_RECRUITING | R21/MM Dosing, Presentations, and Preservatives |
| NCT00125489 | PHASE4 | COMPLETED | CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi |
| NCT00859807 | PHASE4 | COMPLETED | A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects |
| NCT01350856 | PHASE4 | COMPLETED | Tracking Resistance to Artemisinin (TRAC) |
| NCT02089841 | PHASE4 | COMPLETED | Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. |
| NCT03726593 | PHASE4 | UNKNOWN | Drug Combinations of Atovaquone-Proguanil (AP) With ACT |
| NCT03764527 | PHASE4 | COMPLETED | Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar |
| NCT03768908 | PHASE4 | COMPLETED | Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 |
| NCT03773536 | PHASE4 | COMPLETED | Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar |
| NCT03783299 | PHASE4 | COMPLETED | Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic |
| NCT03916003 | PHASE4 | COMPLETED | Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas |
| NCT04829695 | PHASE4 | UNKNOWN | Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon |
| NCT00074841 | PHASE2/PHASE3 | COMPLETED | Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India |
| NCT00158548 | PHASE3 | COMPLETED | ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan |
| NCT00299247 | PHASE3 | WITHDRAWN | SP Resistance and Falciparum Malaria Transmission |
| NCT00403260 | PHASE3 | COMPLETED | Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients |
| NCT00484900 | PHASE3 | COMPLETED | Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria |
| NCT00701961 | PHASE2/PHASE3 | COMPLETED | Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy |
| NCT00709969 | PHASE3 | COMPLETED | Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria |
| NCT01144702 | PHASE2/PHASE3 | COMPLETED | Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum |
| NCT01258049 | PHASE3 | COMPLETED | Superiority of ArTiMist Versus Quinine in Children With Severe Malaria |
| NCT01365598 | PHASE3 | COMPLETED | Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda |
| NCT03923725 | PHASE3 | COMPLETED | A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. |
| NCT03939104 | PHASE3 | COMPLETED | A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia) |
| NCT04147546 | PHASE3 | COMPLETED | Additional Screening With Sensitives RDTs and Malaria |
| NCT04300309 | PHASE2/PHASE3 | TERMINATED | Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria |
| NCT05192265 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine |
| NCT06549257 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant |
| NCT00133393 | PHASE2 | TERMINATED | Pentoxifylline in Children With Malaria |
| NCT00149383 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria |
| NCT00282919 | PHASE2 | COMPLETED | A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria |
| NCT00299208 | PHASE2 | COMPLETED | Azithromycin Combination Therapy for Malaria |
| NCT00312663 | PHASE1/PHASE2 | COMPLETED | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America |
| NCT00312702 | PHASE1/PHASE2 | COMPLETED | Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America |
| NCT00362050 | PHASE2 | COMPLETED | RBx11160 Phase II Dose Ranging Study RBx/MMV05-06 |
| NCT00459615 | PHASE2 | COMPLETED | Phase II Dose Ranging Study of Artesunate |
| NCT00460525 | PHASE2 | COMPLETED | Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali |
| NCT00616304 | PHASE2 | SUSPENDED | Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria |
| NCT01031524 | PHASE1/PHASE2 | COMPLETED | Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ARTESUNATE | 4 | 13 |
| PRIMAQUINE | 4 | 13 |
| AMODIAQUINE | 4 | 12 |
| CHLOROQUINE | 4 | 7 |
| QUININE | 4 | 6 |
| MEFLOQUINE | 4 | 3 |
| PYRIMETHAMINE | 4 | 3 |
| ARTEMETHER | 4 | 2 |
| NITROUS ACID | 4 | 2 |
| ROSIGLITAZONE | 4 | 2 |
| SULFADOXINE | 4 | 2 |
| ARGININE HYDROCHLORIDE | 4 | 1 |
| ARTENIMOL | 4 | 1 |
| LUMEFANTRINE | 4 | 1 |
| PENTOXIFYLLINE | 4 | 1 |
| PIPERAQUINE | 3 | 2 |
| PYRONARIDINE | 3 | 2 |
| DOCONEXENT | 3 | 1 |
| LUMEFANTRINE CO-ARTEMETHER | 3 | 1 |
| RABIES VACCINE | 3 | 1 |
| CYCLOGUANIL | 2 | 2 |
| ALUMINUM PHOSPHATE | 2 | 1 |
| CIPARGAMIN | 2 | 1 |
| DSM-265 | 2 | 1 |
| SUTIDIAZINE | 2 | 1 |
| (S,R)-MEFLOQUINE | 0 | 3 |
| CHEMBL4740236 | 0 | 2 |
| CHEMBL5207162 | 0 | 1 |
| CHEMBL283807 | 0 | 1 |